Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* A male or female participant with a clinical diagnosis of PFIC Type 1 or 2 and with a body weight above 5 kg~* Participant must have clinical genetic confirmation of PFIC-1 or PFIC-2~* Participant must have elevated serum bile acid (s-BA) concentration~* Participant must have history of significant pruritus and a caregiver reported observed scratching in the eDiary~* Participant and/or legal guardian must sign informed consent (and assent) as appropriate.~* Participants will be expected to have a consistent caregiver(s) for the duration of the study~* Caregivers and age-appropriate participants (≥8 years of age) must be willing and able to use an eDiary device as required by the study~Key Exclusion Criteria:~* Participant with pathologic variations of the ABCB11 gene that predict complete absence of the bile salt export pump (BSEP) protein~* Participant with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:~  1. Biliary atresia of any kind~ 2. Benign recurrent intrahepatic cholestasis, indicated by any history of normal s BAs~ 3. Suspected or proven liver cancer or metastasis to the liver on imaging studies~ 4. Histopathology on liver biopsy that is suggestive of alternate non-PFIC related etiology of cholestasis~* Participant with past medical history or ongoing chronic diarrhea~* Any participant with suspected or confirmed cancers except for basal cell carcinoma~* Participant with a past medical history of chronic kidney disease with an impaired renal function and a glomerular filtration rate \<70 mL/min/1.73 m\^2~* Participant with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to start of Screening Period~* Participant has had a liver transplant or a liver transplant is planned within 6 months of randomization~* Decompensated liver disease~* Participant suffers from uncontrolled, recalcitrant pruritic condition other than PFIC~* Participant who has been previously treated with an IBAT inhibitor whose pruritus has not responded to treatment

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A4250 low dose (Type: EXPERIMENTAL): Capsules for oral administration (40 ug/kg) once daily for 24 weeks
- A4250 high dose (Type: EXPERIMENTAL): Capsules for oral administration (120 ug/kg) once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Capsules for oral administration (to match active) once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).